Suppressive effect of frequent ingestion of Lactobacillus johnsonii La1 on Helicobacter pylori colonization in asymptomatic volunteers
Open accessThe DOI matches its Crossref record.
Abstract
Sir, Helicobacter pylori colonization occurs earlier and with a higher frequency in individuals from developing countries who live in conditions of inadequate sanitation than in individuals from industrialized countries. In Chile, for example, between 60% and 70% of the adolescents and >80% of the adults from the low socio-economic stratum are colonized by this pathogen.1 This high prevalence may have important consequences as H. pylori is currently recognized as an aetiological factor of gastroduodenal ulcer and as a risk factor for the development of gastric adenocarcinoma, a highly prevalent cancer in Chile. In most people, however, the presence of H. pylori in the gastric mucosa remains asymptomatic during life, and in consequence it is neither possible nor ethical to eradicate the bacteria colonizing their gastric mucosa with antibiotics. Furthermore, treatment with antibiotics presents other problems related to its high cost for families from the low socio-economic stratum and to the appearance of resistance in H. pylori as well as in other species. For these reasons, it is important to develop low-cost, large-scale alternative solutions applicable to the at-risk population to prevent or decrease H. pylori colonization. In this sense, the use of dietary components capable of interfering with H. pylori, including some vegetables and probiotic microorganisms, appears attractive.2 Some specific strains of exogenous lactobacilli are resistant to the low pH of the stomach and may transiently adhere to the gastric mucosa, where they may exert functional effects. Some of them have been shown to exert in vitro and in vivo bactericidal effects against H. pylori, suggesting that they could possibly interfere with H. pylori colonization in humans.3 This has recently been confirmed by clinical trials. Sakamoto et al.4 reported that Lactobacillus gasseri OLL2716 ingestion suppressed H. pylori infection in adults, but curiously the same strain had no effects in colonized children.5 Using a drinkable, whey-based, spent-culture supernatant of Lactobacillus johnsonii La1 (La1), Michetti et al.6 described decreased H. pylori colonization in adult volunteers; furthermore, we recently observed a significant but low suppressive effect in colonized children after 1 month of La1 ingestion (S. Cruchet, M. C. Obregon, G. Salazar, E. Diaz & M. Gotteland, unpublished data). On the basis of these findings, we proposed to carry out a clinical trial to test whether increasing the frequency of La1 ingestion might result in a higher antagonist effect against H. pylori. Twelve asymptomatic volunteers (two males, 10 females; age: 39.7 ± 11.2 years) H. pylori-positive by 13C-urea breath test (13C-UBT), without previously diagnosed gastrointestinal pathologies or history of antibiotic, antacid or prokinetic drug treatments, were recruited for the study. The protocol was approved by the Ethics Committee of INTA and an ‘informed consent’ form was signed by the subjects who agreed to participate. Volunteers had to ingest 80 mL of a commercial product (Chamyto, Nestlé Chile, Santiago, Chile) containing >107 La1/mL, every 2 h from 08:00 to 22:00 h (i.e. a total of 640 mL of product per day) for 2 weeks. The aim of this design was to increase the duration of the contact between La1, the gastric mucosa and H. pylori. After 1 and 2 weeks of ingesting the product, a second and third 13C-UBT were carried out with a commercial kit (Tau-Kit, Isomed, Madrid, Spain) using 75 mg 13C-urea. The excess δ13CO2 over baseline (DOB) values expressed as were compared for the basal, 1 and 2 week periods. One volunteer (8.3%) presented with diarrhoea during the first 3 days of the study and decided to withdraw. Results (Figure 1) show that DOB values decreased significantly during the course of the study (ANOVA for repeated measurements: F = 4.18, P = 0.034), reflecting a suppressive effect upon H. pylori colonization by La1; after 1 week, DOB2 values [28.92, 95%CI (21.67–36.17)] tended to be lower than DOB1 basal values [46.39; 95%CI (24.20–68.56), P = 0.066] and this decrease reached significance after the second week [DOB3 = 27.39, 95%CI (16.24–38.54), P = 0.043]. Results also showed that the higher the DOB1 basal values, the greater the decrease in DOB values when comparing the basal and 2 week periods (DOB3–DOB1) (Pearson correlation: r = 0.88, P = 0.0015). Our results indicate that continuous ingestion of a La1-containing product at 2 h intervals for a 14 h period every day results in a 40% decrease in DOB values after 2 weeks. This effect is higher than that observed by Sakamoto et al.4 with L. gasseri and comparable to that observed by Michetti et al.6 with a spent-culture supernatant of La1, i.e. a medium much more concentrated than was used in the present study. Whether this effect is due to the higher frequency of product ingestion, or to the total amount of product ingested during the day, is difficult to elucidate. The study is interesting in that
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens
Servin, A. L. (2004) · FEMS Microbiology Reviews · doi:10.1016/j.femsre.2004.01.003 · Cited by 1,236
Lactobacillus spp. for Gastrointestinal Health: Current and Future Perspectives
Dempsey, E., & Corr, S. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840245 · Cited by 579
Probiotics—From Metchnikoff to bioactives
Vasiljevic, T., & Shah, N. P. (2008) · International Dairy Journal · doi:10.1016/j.idairyj.2008.03.004 · Cited by 564
The dual role of bacteriocins as anti- and probiotics
Gillor, O., Etzion, A., & Riley, M. A. (2008) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-008-1726-5 · Cited by 416
The extracellular biology of the lactobacilli
Kleerebezem, M., Hols, P., Bernard, E., Rolain, T., Zhou, M., Siezen, R. J., & Bron, P. A. (2010) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2009.00208.x · Cited by 381
Liévin-Le Moal, V., & Servin, A. L. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00080-13 · Cited by 354
Helicobacter pylori and Probiotics1,
Lesbros-Pantoflickova, D., Corthèsy-Theulaz, I., & Blum, A. L. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.3.812s · Cited by 262
TONG, J. L., RAN, Z. H., SHEN, J., ZHANG, C. X., & XIAO, S. D. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03179.x · Cited by 258
Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori?
GOTTELAND, M., BRUNSER, O., & CRUCHET, S. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02868.x · Cited by 244
Self-citationFrancavilla, R., Lionetti, E., Castellaneta, S. P., Magistà, A. M., Maurogiovanni, G., Bucci, N., De Canio, A., Indrio, F., Cavallo, L., Ierardi, E., et al. (2008) · Helicobacter · doi:10.1111/j.1523-5378.2008.00593.x · Cited by 169
Probiotics Used in Human Studies
Montrose, D. C., & Floch, M. H. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000165649.32371.71 · Cited by 60
Bruno, G., Rocco, G., Zaccari, P., Porowska, B., Mascellino, M. T., & Severi, C. (2018) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2018/6237239 · Cited by 32
Metadata
- Authors
- Gotteland, M.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-04-14
- Volume
- 51
- Issue
- 5
- Pages
- 1317-1319
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2160268203
- Cited by
- 78
- References
- 0
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.